Navigation Links
Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey
Date:11/21/2011

PARSIPPANY, N.J., Nov. 21, 2011 /PRNewswire/ -- Switzerland-based Ferring Pharmaceuticals today announced the purchase of a 25-acre site at 100 Interpace Parkway in Parsippany, N.J.  The new facility will house a state-of-the art, expanded U.S. Operations Center. The expansion is expected to generate jobs in the New Jersey area, countering recent trends in the pharmaceutical industry.

The U.S. Operations Center will be a fully integrated pharmaceutical facility that will house management, administration and support, commercial operations, manufacturing and product development.  It will include a state-of-the-art manufacturing suite, next-generation product development laboratories, a fully equipped education and training conference center, and administrative offices.

"As a private company, Ferring has a long term orientation, as well as a commitment to follow the science to benefit patients. This new facility underscores our long-term commitment to the U.S. market, as well as the State of New Jersey," said Aaron Graff, President and Chief Operating Officer of Ferring Pharmaceuticals, Inc. 

"Together with our Global Research Center in San Diego, this symbolizes our focus on accelerating Ferring growth in the United States.  The local community has continuously expressed support for our endeavors, and we are so pleased to expand our operations in an area with such a large base of talented, highly trained pharmaceutical professionals." 

The Switzerland-based company has experienced consistent double-digit growth in the U.S. and has approximately 600 U.S. employees. Globally Ferring has nearly 5,000 employees with operations in more than 45 countries.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, global pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, LYSTEDA® (tranexamic acid tablets), FIRMAGON® (degarelix for injection), and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

All registered trademarks above are owned by Ferring B.V.

 


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes
2. Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer
3. Ferring Celebrates Winners of 2010 My Little Miracle Essay Contest During National Infertility Awareness Week
4. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
5. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
6. Ferring Pharmaceuticals FIRMAGON® Named Official Sponsor of Ed Randalls Bat for the Cure
7. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
8. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
9. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
10. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
11. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , February 24, 2017 Following ... Israel , s AMAR is a ... 250 M w ound care market in ... BST for inclusion in the National Health ... system   E-QURE Corp. (OTCQB: EQUR), a ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Hemophilia Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Hemophilia market? What are the unit ...
(Date:2/24/2017)... 2017 Medical information groups within the ... self-service capabilities to manage inquiries from external stakeholders ... New research from consulting leader Best Practices, LLC ... website portals where HCPs can sign on and ... many findings to emerge from the new study ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health ... British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition ... Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol treatment ...
(Date:2/26/2017)... TROY, MICHIGAN (PRWEB) , ... February 25, 2017 , ... ... leader Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use ... on the human nervous system and how even small doses can be lethal. , ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, an innovative ... it would be offering some it’s exclusive product line to the public through ... unique baby clothing/feeding products, will team up with AMAZON to distribute a limited ...
(Date:2/26/2017)... ... 26, 2017 , ... Functional imaging data supports improved cognition ... released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , ... in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... on tooth replacement options at his office, Antoine Dental Center. Currently, patients can ... $18,499. Some restrictions may apply, but patients can learn more about these offers ...
Breaking Medicine News(10 mins):